Trends in Parasitology
Volume 30, Issue 9, September 2014, Pages 445-455
Journal home page for Trends in Parasitology

Review
Ivermectin: panacea for resource-poor communities?

https://doi.org/10.1016/j.pt.2014.07.005Get rights and content

Highlights

  • Gairdner Global Health Award given for discovery, development, and use of ivermectin.

  • Ivermectin is one of the world's most successful and promising biomedical compounds.

  • Administration of ivermectin to entire communities improves health and social welfare.

  • Donated ivermectin use will soon eliminate river blindness and elephantiasis globally.

  • Over 300 million poor people take ivermectin annually to treat a range of diseases.

  • Ivermectin has significant promise to combat a variety of diseases of global concern.

  • Extensive research is needed to clarify the potential use of ivermectin in human health.

  • Multidisciplinary, international partnerships hold the key to better public health.

The 2014 Gairdner Global Health Award was conferred for discovery of the unique microorganism that is the sole source of the endectocidal avermectins, and the Public sector/Private sector Partnership that developed innovative biopharmaceuticals with immeasurably beneficial impact on public health worldwide. Ivermectin is already labelled a ‘wonder drug’, essential for campaigns to eliminate two disfiguring and devastating tropical diseases. New uses for it are identified regularly, including possible antibacterial, antiviral, and anticancer potential. Hundreds of millions of people are taking ivermectin to combat various diseases and afflictions, and mass administration of ivermectin in polyparasitised poor communities around the world is increasingly recognised as a mechanism to easily and cost-effectively improve overall health and quality of life for everyone.

Section snippets

Need for effective antiparasitics

At a time when the WHO warns that we are facing the daunting future of a world without antibiotics, it is encouraging and comforting to know that some drugs are maintaining, or improving, their impact on public health. Of all the biopharmaceutical products ever discovered, developed, and deployed to maintain or improve human health and welfare, ivermectin is perhaps one of the most diverse, useful, and successful. This was recognised by bestowing of the 2014 Gairdner Global Health Award for the

Ivermectin discovery

In one of the world's most effectual Public/Private Partnerships, in 1973 the Kitasato Institute in Japan joined forces with the Merck Sharpe & Dohme Research Laboratories (MSDRL) in the USA in a search for new and innovative antibiotics. The discovery of the avermectin-producing microorganism, S. avermitilis (Streptomyces avermectinius) at the Kitasato Institute in 1973 was accomplished by a small research group. A unique and structurally very different organism was isolated from a soil sample

Compound characteristics and potential

The avermectins were discovered in 1975 and proved to be broad-spectrum antiparasitic compounds with the ability to kill parasites both inside and outside the body 15, 16, 17, 18, 19. This engendered creation of the term ‘endectocide’ to describe a novel class of chemical compound. They were unprecedented, effective orally, topically or parenterally and at very low doses. They were radically different and lacked cross-resistance with any existing commonly used antiparasitic compounds,

Donated ivermectin

Following unmatched success in the animal health market, Merck scientists soon realised that the anthelmintic potency of ivermectin could help to conquer filarial diseases in humans. Merck joined forces with the WHO, nongovernmental organisations, international donors, governments, and affected communities to drive forward the testing of the drug and registration for large-scale community use [13]. Subsequently, ivermectin (as Mectizan®) was registered for human use by French authorities in

New potential

In addition to the gradual appreciation of the diverse health and socioeconomic benefits that ivermectin use can provide, research is beginning to shed light on the promise of ivermectin and the prospects of it combatting a range of diseases and killing vectors of disease-causing parasites. The following is not the outcome of an exhaustive search of the literature and research under way, it is simply meant to serve as an indicator of the potential that has been identified thus far, and perhaps

Insecticidal

In terms of disease vector control, ivermectin is known to be highly effective in killing a variety of insects 64, 65 A comprehensive examination was carried out testing avermectins against 84 species of insects, covering ten orders, the majority being significant pests of livestock, crops, and of nuisance and health impact in human populations. The avermectins proved toxic to almost all the insects tested, which demonstrated water balance difficulties, as well as disruption of moulting and

Antiviral

For most of the past 40 years, ivermectin was not known to have any antiviral characteristics. Yet recent research has confounded this belief. Ivermectin has been demonstrated to be a broad-spectrum inhibitor of importin α/β nuclear import. Consequently, it has been shown to have potent antiviral activity towards HIV-1 and dengue viruses, both of which are dependent on the importin protein superfamily for several key cellular processes. Ivermectin may be of significance in disrupting HIV-1

Antibacterial

Up until recently, the avermectins were also believed to lack antibacterial activity. However, in 2012, reports emerged that ivermectin was capable of preventing infection of epithelial cells by the bacterial pathogen Chlamydia trachomatis, and to do so at doses that could be used to counter sexually-transmitted or ocular infections [85]. In 2013, researchers further reported that ivermectin appeared to be bactericidal against a range of mycobacterial species, including against multidrug

Anticancer

Owing to its ability to induce membrane hyperpolarisation, ivermectin has now been shown to promote cell death in leukaemia cells, with researchers claiming that ivermectin could be rapidly advanced into clinical trials [88]. The anticancer potential has been supported by recent reports that ivermectin demonstrates activity against chronic lymphocytic leukaemia (CLL) cells and against ME-180 cervical cancer cells [89]. Furthermore, ivermectin has been shown to potentiate doxorubicin-induced

Schistosomiasis

A research collaboration was established between the Kitasato Institute and Fiocruz in Brazil in 2008 to test ivermectin analogues and compounds from the chemical libraries of each institute in screening systems being operated in the two institutions. Promising results were immediately found with regard to the impact of ivermectin on the intermediate host snails responsible for maintaining the schistosomiasis re-infection cycle, offering the prospect of using ivermectin to help control one of

Concluding remarks

A panacea is a Greek-rooted word used to define a remedy for all ills or diseases. Mass administration of ivermectin to all members of poor, polyparasitised communities brings fresh meaning to the concept of a remedy for all, improving health and economic welfare for almost everyone, in both the short and long term (Figure 6).

Ivermectin is recognised as being a comparatively safe drug for human use. In veterinary use, ivermectin can induce severe adverse drug reactions. There are several

References (92)

  • S. Sharmeen

    The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells

    Blood

    (2010)
  • T.G. Geary

    Ivermectin 20 years on: maturation of a wonder drug

    Trends Parasitol.

    (2005)
  • R. Spear et al.

    Mass treatment with ivermectin: an underutilized public health strategy

    Bull. World Health Organ.

    (2004)
  • R.W. Burg

    Avermectins, new family of potent anthelmintic agents: producing organisms and fermentation

    Antimicrob. Agents Chemother.

    (1979)
  • E.O. Stapley et al.

    Avermectins, antiparasitic lactones produced by Streptomyces avermitilis isolated from a soil in Japan

  • W. Shoop et al.

    Ivermectin abamectin and eprinomectin

  • J.C. Chabala

    Ivermectin, a new broad-spectrum antiparasitic agent

    J. Med. Chem.

    (1980)
  • W.C. Campbell

    Ivermectin: a potent antiparasitic agent

    Science

    (1983)
  • R.W. Burg et al.

    Isolation and characterization of the producing organism

  • E. Ottesen et al.

    Ivermectin in human medicine

    J. Antimicrob. Chemother.

    (1994)
  • T. Fujisaki et al.

    TDR's Contribution to the Development of Ivermectin for Onchocerciasis

    (1998)
  • S. Ōmura et al.

    The life and times of ivermectin: a success story

    Nat. Rev. Microbiol.

    (2005)
  • A. Crump et al.

    Ivermectin, “Wonder drug” from Japan: the human use perspective

    Proc. Jpn. Acad. Ser. B: Phys. Biol. Sci.

    (2011)
  • W.C. Campbell

    History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents

    Curr. Pharm. Biotechnol.

    (2012)
  • J.R. Egerton

    Avermectins, new family of potent anthelmintic agents: efficacy of the B1 component

    Antimicrob. Agents Chemother.

    (1979)
  • W.C. Campbell

    An introduction to the avermectins

    N. Z. Vet. J.

    (1981)
  • D.A. Ostlind

    Insecticidal activity of the parasitic avermectins

    Vet. Rec.

    (1979)
  • I. Putter

    Avermectins: novel insecticides, acaricides and nematicides from a soil microorganism

    Experientia

    (1981)
  • W.C. Campbell et al.

    Ivermectin: a review of efficacy and safety

    J. Vet. Pharmacol. Ther.

    (1984)
  • M.H. Fisher et al.

    Chemistry

  • W.C. Campbell

    The genesis of the antiparasitic drug, ivermectin

  • M.J. Turner et al.

    Mode of action of ivermectin

  • European Medicines Agency

    Committee for Medicinal Products for Veterinary Use: Ivermectin

    (2004)
  • W.C. Campbell

    Efficacy of the avermectins against filarial parasites: a short review

    Vet. Res. Commun.

    (1981)
  • D. Barth et al.

    Investigations of the efficacy of ivermectin against ectoparasites in cattle

    Zentral. Bakt. Parasit. Infect. Hyg.

    (1980)
  • C. Centurier et al.

    On the efficacy of ivermectin versus ticks (O. moubata, R. appendiculatus and A. variegatum) in cattle

    Zentral. Bakt. Parasit. Infect. Hyg.

    (1980)
  • H.R. Taylor et al.

    The status of ivermectin in the treatment of human onchocerciasis

    Am. J. Trop. Med. Hyg.

    (1989)
  • International Task Force for Disease Eradication

    Summary of the 22nd Meeting of the International Task Force for Disease Eradication (II), January 14th, 2014

    (2014)
  • Mectizan Donation Program

    Annual Highlights: The Accomplishments of the Mectizan Donation Program in its 26th Year

    (2014)
  • L.E. Coffeng

    African Programme for Onchocerciasis Control 1995-2015: model-estimated health impact and cost

    PLoS Negl. Trop. Dis.

    (2013)
  • World Health Organization

    Regional Strategic Plan for Neglected Tropical Diseases in the African Region 2014-2020

    (2013)
  • P. Gonzalez

    Ivermectin in human medicine, an overview of the current status of its clinical applications

    Curr. Pharm. Biotechnol.

    (2012)
  • World Health Organization

    Strongyloidiasis: Key Facts

    (2014)
  • N. Ohtaki

    Oral ivermectin treatment in two cases of scabies: effective in crusted scabies induced by corticosteroid but ineffective in nail scabies

    J. Dermatol.

    (2003)
  • K. Karthikeyan

    Treatment of scabies: newer perspectives

    Postgrad. Med. J.

    (2005)
  • D. Pilger

    Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded trial

    Bull. World Health Organ.

    (2010)
  • Cited by (0)

    View full text